NCT06130046View on ClinicalTrials.gov

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

December 1, 2026

Conditions
Kidney Transplant; ComplicationsLiver Transplant; Complications
Interventions
BIOLOGICAL

MR-proADM dosage

Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U

Trial Locations (1)

00133

RECRUITING

University of Rome Tor Vergata, Rome

All Listed Sponsors
lead

University of Rome Tor Vergata

OTHER